IA
KLRS

IFP Advisors’s Kalaris Therapeutics KLRS Stock Holding History

IFP Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-130
Closed -$1.26K – 4686
2024
Q4 		$1.26K Hold
130
– – ﹤0.01% 3234
2024
Q3 		$2.43K Hold
130
– – ﹤0.01% 2868
2024
Q2 		$2.17K Buy
+130
New +$2.29K ﹤0.01% 2793
2023
Q1 		– Hold
0
– -$1K – 4497
2022
Q4 		– Hold
0
– – – 4530
2022
Q3 		– Hold
0
– – – 4718

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's KLRS Position: Q1 2025 in Review

IFP Advisors sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 130 shares — an estimated $1.26K sold.

IFP Advisors first reported a position in KLRS in Q2 2024 and held it in 3 quarters. The position peaked at $2.43K in Q3 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • IFP Advisors reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • IFP Advisors sold 130 Kalaris Therapeutics shares in Q1 2025, an estimated $1.26K.
  • IFP Advisors first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 3 quarters.
  • IFP Advisors's Kalaris Therapeutics position peaked at $2.43K in Q3 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on IFP Advisors's 13F filing for Q1 2025, filed 5 May 2025.